Data presented at ISTH2020 strengthens evidence for both Elocta ® and Alprolix ® in previously untreated patients with haemophilia
Final results from the PUPs A-LONG and PUPs B-LONG studies assessing the efficacy and safety of Elocta® (efmoroctocog alfa) and Alprolix® (eftrenonacog alfa) in previously untreated patients (PUPs) with haemophilia A and B respectively were presented at the ISTH2020 (International Society on Thrombosis and Haemostasis) Virtual Congress, July 12-14. The results were presented jointly by Sobi™ and Sanofi, collaborators in the development and commercialisation of Alprolix and Elocta/ELOCTATE. “These are the first published final results for extended half-life (EHL)